Ezetimibe use 'should be last resort', DTB says
By Nigel Praities
GPs should ‘make every effort' to lower cholesterol levels with statins rather than resort to using ezetimibe, an analysis by a BMJ publication has concluded.
A review of the data on ezetimibe – published in the journal Drug and Therapeutics Bulletin this month – concludes the drug is expensive and the long-term benefit is ‘not known.'
The review goes further than NICE guidance, which recommends ezetimibe as an add-on therapy in those who do not achieve their LDL-cholesterol goals with a statin.
The paper says trials ‘have failed to prove any clinical outcomes' or any improvement in tolerability and statins should be used routinely.
A spokesperson from the manufacturer, Merck, said an ongoing trial would provide more data on the effect of ezetimibe on clinical outcomes.